Open AccessInfluence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen
Author(s) -
Xiaoqin Zhu,
Jia Zhu,
Feifei Sun,
Zijun Zhen,
DaLei Zhou,
Suying Lü,
Junting Huang,
Yi Que,
Lian Zhang,
Ruiqing Cai,
Juan Wang,
Yizhuo Zhang
Publication year - 2021
Publication title -
pharmacogenomics and personalized medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.845
H-Index - 28
ISSN - 1178-7066
DOI - 10.2147/pgpm.s292556
Subject(s) - medicine , irinotecan , refractory (planetary science) , regimen , toxicity , sn 38 , oncology , pharmacology , cancer , colorectal cancer , physics , astrobiology
The association between UGT1A1*6/*28 polymorphisms and treatment outcomes of irinotecan in children remains unknown. This retrospective study investigated the influence of UGT1A1*6/*28 polymorphisms on irinotecan toxicity and survival of pediatric patients with relapsed/refractory solid tumors.